The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens
Abstract
BACKGROUND: Catheter-related bloodstream infections (CR-BSIs) are associated with substantial mortality, prolongation of hospital stay, and increased cost of care. Dalbavancin, a new glycopeptide antibiotic with unique pharmacokinetic properties that have allowed clinical development of a weekly dosing regimen, possesses excellent activity against clinically important gram-positive bacteria, suggesting utility in the treatment of patients with CR-BSIs. METHODS: A phase 2, open-label, randomized, controlled, multicenter study of 75 adult patients with CR-BSIs compared treatment with intravenous dalbavancin, administered as a single 1000-mg dose followed by a 500-mg dose 1 week later, with intravenous vancomycin, administered twice daily for 14 days. Gram-positive bacteria isolated in this study included coagulase-negative staphylococci (CoNS) and Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). RESULTS: Infected patients who received weekly dalbavancin (n=33) had an overall success rate (87.0%; 95% confidence interval [CI], 73.2%-100.0%) that was significantly higher than that of those who received vancomycin (n=34) (50.0%; 95% CI, 31.5%-68.5%). Adverse events and laboratory abnormalities were generally mild and were comparable for the 2 drugs. CONCLUSIONS: Dalbavancin thus appears to be an effective and well-tolerated treatment option for adult patients with CR-BSIs caused by CoNS and S. aureus, including MRSA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
A Semiquantitative Culture Method for Identifying Intravenous-Catheter-Related Infection
Maki, D. G., Weise, C. E., & Sarafin, H. W. (1977) · New England Journal of Medicine · doi:10.1056/nejm197706092962301 · Cited by 2,027
Guidelines for the management of intravascular catheter-related infections
Mermel, L. A., Farr, B. M., Sherertz, R. J., Raad, I. I., O'Grady, N., Harris, J. S., & Craven, D. E. (2001) · Clinical Infectious Diseases · doi:10.1086/320001 · Cited by 1,449
Self-citationNosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Pittet, D. (1994) · JAMA · doi:10.1001/jama.1994.03510440058033 · Cited by 926
Intravascular-catheter-related infections
Raad, I. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10006-x · Cited by 627
Self-citationLevine, D. P., Fromm, B. S., & Reddy, B. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-674 · Cited by 577
Chang, F.-Y., Peacock, J. E., Musher, D. M., Triplett, P., MacDonald, B. B., Mylotte, J. M., O’Donnell, A., Wagener, M. M., & Yu, V. L. (2003) · Medicine · doi:10.1097/01.md.0000091184.93122.09 · Cited by 530
Infectious Complications of Indwelling Vascular Catheters
Raad, I. I., & Bodey, G. P. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/15.2.197 · Cited by 446
Self-citationVancomycin for Staphylococcus aureus endocarditis in intravenous drug users
Small, P. M., & Chambers, H. F. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.1227 · Cited by 399
Sherertz, R. J., Raad, I. I., Belani, A., Koo, L. C., Rand, K. H., Pickett, D. L., Straub, S. A., & Fauerbach, L. L. (1990) · Journal of Clinical Microbiology · doi:10.1128/jcm.28.1.76-82.1990 · Cited by 381
Self-citationDimick, J. B. (2001) · Archives of Surgery · doi:10.1001/archsurg.136.2.229 · Cited by 341
Staphylococcus aureus bacteremia
Nolan, C. M., & Beaty, H. N. (1976) · The American Journal of Medicine · doi:10.1016/0002-9343(76)90715-4 · Cited by 314
Seltzer, E., Dorr, M. B., Goldstein, B. P., Perry, M., Dowell, J. A., Henkel, T., & Dalbavancin Skin and Soft-Tissue Infection Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/379015 · Cited by 231
Self-citationChambers, H. F., Miller, R. T., & Newman, M. D. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-8-619 · Cited by 214
Farber, B. F., Kaplan, M. H., & Clogston, A. G. (1990) · Journal of Infectious Diseases · doi:10.1093/infdis/161.1.37 · Cited by 211
Evans, R. C., & Holmes, C. J. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.6.889 · Cited by 199
Raad, I., Chatzinikolaou, I., Chaiban, G., Hanna, H., Hachem, R., Dvorak, T., Cook, G., & Costerton, W. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3580-3585.2003 · Cited by 166
Self-citationIn-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic
Candiani, G., Abbondi, M., Borgonovi, M., Romanò, G., & Parenti, F. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.2.179 · Cited by 150
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates
Streit, J. M., Fritsche, T. R., Sader, H. S., & Jones, R. N. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2003.09.004 · Cited by 144
Nosocomial Bloodstream Infection and Clinical Sepsis
Hugonnet, S., Sax, H., Eggimann, P., Chevrolet, J.-C., & Pittet, D. (2004) · Emerging infectious diseases · doi:10.3201/eid1001.030407 · Cited by 129
Importance of nondrug costs of intravenous antibiotic therapy
van Zanten, A. R. H., Engelfriet, P. M., van Dillen, K., van Veen, M., Nuijten, M. J. C., & Polderman, K. H. (2003) · Critical Care · doi:10.1186/cc2388 · Cited by 82
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
Turner, N. A., Sharma-Kuinkel, B. K., Maskarinec, S. A., Eichenberger, E. M., Shah, P. P., Carugati, M., Holland, T. L., & Fowler, V. G. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0147-4 · Cited by 2,051
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
Intravascular catheter-related infections: advances in diagnosis, prevention, and management
Raad, I., Hanna, H., & Maki, D. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70235-9 · Cited by 525
Self-citationClinical Management of Staphylococcus aureus Bacteremia: A Review
Holland, T. L., Arnold, C., & Fowler, V. G. (2014) · JAMA · doi:10.1001/jama.2014.9743 · Cited by 449
Metadata
- Authors
- Raad, I., Darouiche, R., Vazquez, J., Lentnek, A., Hachem, R., Hanna, H., Goldstein, B., Henkel, T., & Seltzer, E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-02-01
- Volume
- 40
- Issue
- 3
- Pages
- 374-380
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2107770752
- Cited by
- 292
- References
- 22
- FWCI
- 36.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.